Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 739

1.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.

Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.

J Gynecol Oncol. 2016 Jan;27(1):e7. doi: 10.3802/jgo.2016.27.e7. Epub 2015 Nov 27.

2.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

3.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
4.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

5.

WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.

Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A.

BMC Cancer. 2006 Apr 11;6:90.

6.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746. Masson, A-M M [corrected to Mes-Masson, A-M].

7.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.

8.

Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer.

Abd El hafez A, El-Hadaad HA.

Ann Diagn Pathol. 2014 Apr;18(2):58-62. doi: 10.1016/j.anndiagpath.2013.11.004. Epub 2013 Nov 23.

PMID:
24342665
9.

SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.

Yang M, Xie X, Ding Y.

Oncol Rep. 2016 Mar;35(3):1796-806. doi: 10.3892/or.2016.4545. Epub 2016 Jan 5.

PMID:
26750614
10.

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.

Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.

Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.

11.

Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma.

Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Ough F, Liu S, Pejovic T, Lele S.

Gynecol Oncol. 2012 Oct;127(1):198-201. doi: 10.1016/j.ygyno.2012.06.012. Epub 2012 Jun 15.

12.

Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.

Ren C, Du J, Xi C, Yu Y, Hu A, Zhan J, Guo H, Fang W, Liu C, Zhang H.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):187-94. doi: 10.1016/j.bbrc.2014.02.087. Epub 2014 Feb 27.

PMID:
24583125
13.

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.

Park SH, Song JY, Kim YK, Heo JH, Kang H, Kim G, An HJ, Kim TH.

Int J Oncol. 2014 Mar;44(3):637-46. doi: 10.3892/ijo.2013.2232. Epub 2013 Dec 30.

14.

[Expression and promotor methylation of p73 gene in ovarian epithelial tumors].

Zhang YL, Guo XR, Shen DH, Cheng YX, Liang XD, Chen YX, Wang Y.

Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):33-8. Chinese.

PMID:
22455848
15.

Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.

Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K.

Oncol Rep. 2005 Jun;13(6):1153-8.

PMID:
15870936
16.

Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.

Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S.

Hum Pathol. 2013 Aug;44(8):1465-71. doi: 10.1016/j.humpath.2012.12.016. Epub 2013 Mar 1.

PMID:
23465277
17.

High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.

Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas S, Silva-Ayala R, Almaraz M, Méndez C.

J Ovarian Res. 2016 Jul 7;9(1):41. doi: 10.1186/s13048-016-0247-6.

18.

Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis.

Espinosa I, Catasus L, Canet B, D'Angelo E, Muñoz J, Prat J.

Mod Pathol. 2011 Jun;24(6):846-54. doi: 10.1038/modpathol.2011.12. Epub 2011 Feb 11.

19.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

20.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760

Supplemental Content

Support Center